MedImmune Inc. infectious diseases/aids, transplantation news

MEDI entered into an agreement to settle a December 1993 class action lawsuit for $4.25 million. The suit alleged that certain MEDI officers and directors failed to disclose material information and made misleading statements concerning the likelihood of FDA licensure of RespiGam for respiratory syncytial virus.

MEDI continues to deny all of the allegations. RespiGam was recommended for approval by an FDA advisory panel last month (see BioCentury Dec. 18). ...